Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Pintado V, López-Vélez R. HIV-associated visceral leishmaniasis. Clin Microbiol Infect 2001 (en prensa)
[2.]
J. Alvar, C. Canavate, S.B. Gutiérrez, M. Jiménez, F. Laguna, R. López-Vélez, et al.
Leishmania and human immunodeficiency virus coinfection: the first 10 years.
Clin Microbiol Rev, 10 (1997), pp. 298-319
[3.]
V. Pintado, P. Martín-Rabadán, M. Rivera, S. Moreno, E. Bouza.
Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non- HIV-infected patients: a comparative study.
Medicine (Baltimore), 80 (2001), pp. 54-73
[4.]
R. López-Vélez, J. Pérez-Molina, A. Guerrero, F. Baquero, J. Villarrubia, L. Escribano, et al.
Clinico-epidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain.
Am J Trop Med Hyg, 58 (1998), pp. 436-443
[5.]
World Health Organization. Leishmania/HIV co-infection, south-western Europe, 1990-1998. Retrospective analysis of 965 cases.
Wkly Epidemiol rec, 74 (1999), pp. 365-375
[6.]
World Health Organization. Leishmania/HIV co-infection. Epidemiological analysis of 692 retrospective cases.
Wkly Epidemiol Rec, 72 (1997), pp. 49-54
[7.]
M. Delgado, M.A. García, F. Martos, J.M. Reguera, F. Jiménez, J. Colmenero.
Características clínicas y evolutivas de la leishmaniasis visceral en pacientes con infección por VIH.
An Med Interna, 14 (1997), pp. 506-510
[8.]
F.J. Medrano, J. Hernández, E. Jiménez, J.A. Pineda, A. Rivero, A. Sánchez.
Visceral leishmaniasis in HIV-1-infected individuals: a commonopportunistic infection in Spain?.
AIDS, 6 (1992), pp. 1499-1503
[9.]
S. Reus, R. Sánchez, J. Portilla, V. Boix, M. Priego, E. Merino, et al.
Leishmaniasis visceral: estudio comparativo de pacientes con y sin infección por el virus de la inmunodeficiencia humana.
Enferm Infecc Microbiol Clin, 17 (1999), pp. 515-520
[10.]
World Health Organization. Report on the consultative meeting on Leishmania/ HIV co-infection. 1995; Geneve, Switzerland. World Health Organization. WHO/LEISH/95.35: 1 p. 1995
[11.]
F. Laguna, M. Adrados, J. Alvar, V. Soriano, M.E. Valencia, V. Moreno, et al.
Visceral leishmaniasis in patients infected with the human immunodeficiency virus.
Eur J Clin Microbiol Infect Dis, 16 (1997), pp. 898-903
[12.]
R. López-Vélez, J. Casado, V. Pintado.
Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART).
Clin Microbiol Infect, 7 (2001), pp. 270-271
[13.]
M. Tumbarello, E. Tacconelli, S. Bertagnolio, R. Cauda.
Highly active antiretroviral therapy decreases in the incidence of visceral leishmaniasis in HIV-infected individuals.
AIDS, 14 (2000), pp. 2948-2949
[14.]
M. Jiménez-Expósito, C. Alonso-Villaverde, P. Sarda, L. Masana.
Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy.
AIDS, 14 (1999), pp. 152-153
[15.]
R. De la Rosa, J.A. Pineda, J. Delgado, J. Macías, F. Morillas, S.J. Martín, et al.
Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients.
Clin Infect Dis, 32 (2001), pp. 633-635
[16.]
J. Alvar, S.B. Gutiérrez, I. Pachón, E. Calbacho, M. Ramírez, R. Vallés, et al.
AIDS and Leishmania infantum. New approaches for a new epidemiological problem.
Clin Dermatol, 14 (1996), pp. 541-546
[17.]
C. Montalbán, J.L. Calleja, A. Erice, F. Laguna, B. Clotet, D. Podzamczer, et al.
Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS.
J Infect, 21 (1990), pp. 261-270
[18.]
J. Berenguer, S. Moreno, E. Cercenado, J.C. Bernaldo de Quirós, A. García de la Fuente, E. Bouza.
Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV).
Ann Intern Med, 111 (1989), pp. 12-132
[19.]
H. Albrecht, I. Sobottka, C. Emminger, H. Jablonowski, G. Just, A. Stoehr, et al.
Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani.
Arch Pathol Lab Med, 120 (1996), pp. 189-198
[20.]
L. Gradoni, A. Scalone, M. Gramiccia.
HIV-Leishmania co-infection in Italy: serological data as an indication of the sequence of acquisition of the two infections.
Trans R Soc Trop Med Hyg, 87 (1993), pp. 94-96
[21.]
J. Kubar, P. Marty, A. Lelievre, J.F. Quaranta, P. Staccini, B.C. Caroli, et al.
Visceral leishmaniasis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts.
AIDS, 12 (1998), pp. 2147-2153
[22.]
E. Rosenthal, P. Mary, P. Del Giudice, C. Pradier, C. Ceppi, J.A. Gastaut, et al.
HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania.
Clin Infect Dis, 31 (2000), pp. 1093-1095
[23.]
E. Rosenthal, P. Marty, M.I. Poizot, J. Reynes, F. Pratlong, A. Lafeuillade, et al.
Visceral leishmaniasis and HIV-1 co-infection in southern France.
Trans R Soc Trop Med Hyg, 89 (1995), pp. 159-162
[24.]
R. López-Vélez, F. Laguna, J. Alvar, J.A. Pérez-Molina, R. Molina, P. Martínez, et al.
Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
J Clin Microbiol, 33 (1995), pp. 937-939
[25.]
R. Piarroux, F. Gambarelli, H. Dumon, M. Fontes, S. Dunan, C. Mary.
Comparison of PCR with direct examination of bone marrow aspiration, myeloculture and serology for diagnosis of visceral leishmaniasis in immunocompromised patients.
J Clin Microbiol, 32 (1994), pp. 746-749
[26.]
L. Gradoni, A. Bryceson, P. Desjeux.
Treatment of Mediterranean visceral leishmaniasis.
Bull World Health Organ, 73 (1995), pp. 191-197
[27.]
F. Laguna, R. López-Vélez, V. Soriano, P. Montilla, J. Alvar, J. González.
Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV.
J Infect, 28 (1994), pp. 255-259
[28.]
F. Laguna, R. López-Vélez, F. Pulido, A. Salas, C.J. Torre, E. Torres, et al.
Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
AIDS, 13 (1999), pp. 1063-1069
[29.]
R. Russo, L.C. Nigro, S. Minniti, A. Montineri, L. Gradoni, L. Caldeira, et al.
Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).
J Infect, 32 (1996), pp. 133-137
[30.]
F. Laguna, C.J. Torre, V. Moreno, J.L. Villanueva, E. Valencia.
Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus.
Clin Infect Dis, 21 (1995), pp. 711-712
[31.]
R. Davidson, R. Russo.
Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B.
Clin Infect Dis, 19 (1994), pp. 560
[32.]
M. López-Dupla, A. Gil, P. Lavilla, V. Pintado, E. Valencia, M.P. Martínez, et al.
Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases.
J Antimicrob Chemother, 32 (1993), pp. 657-659
[33]
Laguna F, Videla S, Jiménez ME, and the Spanish HIV-Leishmania Study Group. Amphotericin B lipid complex vs meglumine antimoniate in the treatment of visceral leishmaniasis in HIV-infected patients: a multicenter, open-label with blinded centralized randomisation and parallel clinical trial (abstract 33). 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 2001
[34.]
J. Delgado, J. Macías, J.A. Pineda, J.E. Corzo, M.M. González, R. de la Rosa, et al.
High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
Am J Trop Med Hyg, 61 (1999), pp. 766-769
[35.]
Pasquau F, Ena J, Sánchez R, the Mediterranean Group of Leishmania/HIV Study. Leishmania and HIV infection: a collaborative study of 228 cases in a Spanish Mediterranean area (abstract TuOrB357). 13th International AIDS Conference, Durban, South Africa, 2001
[36.]
E. Ribera, I. Ocaña, J. de Otero, E. Cortés, I. Gasser, A. Pahissa.
Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
Am J Med, 100 (1996), pp. 496-501
[37.]
J. Berenguer, J. Cosín, P. Miralles, J. López, B. Padilla.
Discontinuation of anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy.
AIDS, 14 (2001), pp. 2948-2950
[38.]
J. Casado, R. López-Vélez, V. Pintado, C. Quereda, A. Antela, S. Moreno.
Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy.
Eur J Clin Microbiol Infect Dis, 20 (2001), pp. 202-205
[39.]
J.L. Villanueva, A. Alarcón, M. Bernabeu-Wittel, E. Cordero, D. Prados, C. Regordán, et al.
Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of the highly active antiretroviral therapy.
Eur J Clin Microbiol Infect Dis, 19 (2000), pp. 798-801
[40.]
E. Ribera, E. Cucurull, I. Ocaña, T. Vallespi, I. Gasser, C. Juste.
Leishmaniasis visceral en pacientes con infección por VIH.
Enferm Infecc Microbiol Clin, 13 (1995), pp. 73-79
[41.]
Pintado V, Moreno S, Miralles P, Pérez-Tascón M, García JJ, Bouza E. Prolonged survival after highly active antiretroviral therapy (HAART) in AIDS-associated visceral leishmaniasis (abstract WePeA4025). 13th International AIDS Conference, Durban, South Africa, 2001
[42.]
Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.
Morb Mortal Wkly Rep, 41 (1992), pp. 1-19
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
